Management of Hemophilia Patients with Inhibitors

Bjoern, 1986, Activation of coagulation factor VII to VIIa, Research Disclosure, 269, 564 Brackmann, 1982, The treatment of inhibitors against factor VIII by continuous treatment with factor VII and activated prothrombin complex concentrates. Activated Prothrombin Complex Concentrates, 194 Brackman, 1984, Induced immunotolerance in factor VIII inhibitor patients, Prog Clin Biol Res, 150, 181 Brinkhous, 1989, Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia, hemophilia B, and von Willebrand disease, Proc Natl Acad Sci USA, 86, 1382, 10.1073/pnas.86.4.1382 Gringeri, 1991, Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody, Haemostasis, 21, 1 Grupp, 1989, Recalcitrant epistaxis in a hemophiliac with inhibitors: Experience with recombinant factor VIIa (abstract 1489), Blood, 74, 3901 Hagen, 1986, Characterization of a cDNA coding for human factor VII, Proc Natl Acad Sci USA, 83, 2412, 10.1073/pnas.83.8.2412 Hay, 1990, Induction of immune-tolerance in patients with haemophilia A and inhibitors treated with porcine VIIIC by home-therapy, Blood, 76, 882, 10.1182/blood.V76.5.882.882 Hedner, 1983, Induced tolerance in hemophilia patients with antibodies against IX:C, Acta Med Scand, 214, 191, 10.1111/j.0954-6820.1983.tb08594.x Hedner, 1985, Management of haemophilia A with antibodies—the effect of combined treatment with factor VIII, hydrocortisone and cyclophosphamide, Thromb Haemost, 54, 776, 10.1055/s-0038-1660131 Hedner, 1983, Use of human factor VIIa in the treatment of two hemophilia A patients with high-titre inhibitors, J Clin Invest, 71, 1836, 10.1172/JCI110939 Hedner, 1989, Clinical experience with human plasma-derived factor VIIa in patients with hemophilia A and high-titer inhibitors, Haemostasis, 19, 335 Hedner, 1990, Comparison of the effect of plasma-derived and recombinant human FVIIa in vitro and in a rabbit model, Blood Coagulation and Fibrinolysis, 1, 145 Hedner, 1988, Successful use of rFVIIa in a patient with severe hemophilia A subjected to synovectomy, Lancet, 2, 1193, 10.1016/S0140-6736(88)90259-0 Hedner, 1991, Recombinant FVIIa in hemophilia treatment, 283 Ingerslev, 1991, Control of hemostasis with recombinant factor VIIa in a patient with inhibitors to FVIII, Lancet, 338, 831, 10.1016/0140-6736(91)90729-9 Kernoff, 1984, Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII, Blood, 63, 31, 10.1182/blood.V63.1.31.31 Lusher, 1980, Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: A multicenter therapeutic trial, N Engl J Med, 303, 421, 10.1056/NEJM198008213030803 Lusher, 1991, The role of prothrombin complex concentrates and factor VIII concentrates (human and porcine) in management of bleeding episodes in inhibitor patients. Hemophilia and von Willebrand’s Disease in the 1990s, 271 Macik, 1989, Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor, Am J Hematol, 32, 232, 10.1002/ajh.2830320315 Mauser-Bunschoten, 1991, Immune tolerance: A 1990 approach. Hemophilia and von Willebrand’s Disease in the 1990s, 265 Nilsson, 1973, Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide, Ann Intern Med, 78, 91, 10.7326/0003-4819-78-1-91 Nilsson, 1976, Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX, Scand J Haematol, 16, 369, 10.1111/j.1600-0609.1976.tb00330.x Nilsson, 1988, Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII, N Engl J Med, 318, 947, 10.1056/NEJM198804143181503 Nilsson, 1981, A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: Substitution therapy and surgery in a patient with hemophilia A and antibodies, Blood, 58, 38, 10.1182/blood.V58.1.38.38 Nilsson, 1984, Extracorporeal protein A-sepharose and specific affinity chromatography for removal of antibodies, Prog Clin Biol Res, 150, 225 Rizza, 1984, The management of haemophiliacs who have antibodies to factor VIII, Scand J Haematol (Suppl), 40, 187 Scheibel, 1987, Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: A description of eleven patients treated, Thromb Haemost, 58, 1049, 10.1055/s-0038-1646054 Schimpf, 1982, Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with haemophilia A, Lancet, 2, 1043, 10.1016/S0140-6736(82)90071-X Schmidt, 1991, Prolonged recombinant activated factor VII (rFVIIa. Treatment for severe bleeding and surgical hemotasis in a factor IX- deficient patient with an inhibitor, Br J Haematol, 78, 460, 10.1111/j.1365-2141.1991.tb04468.x Sjamsoedin, 1981, The effect of activated prothrombin complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII, N Engl J Med, 305, 717, 10.1056/NEJM198109243051301 Stein SF, Duncan A, Cutler D, et al: Disseminated intravascular coagulation (DIC) in a hemophiliac treated with recombinant factor Vila. International Society of Hematology 23rd Congress/ASH 32nd Annual Meeting, Boston, MA, August 1990 Sullivan, 1984, Fatal myocardial infarction following therapy with prothrombin complex concentrates in a young man with hemophilia A, Pediatrics, 74, 279, 10.1542/peds.74.2.279 Thim, 1988, Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells, Biochemistry, 27, 7785, 10.1021/bi00420a030 Wensley, 1985, Induction of tolerance to factor VIII in hemophilia with inhibitors using low doses of factor VIII, Thromb Haemost, 54, 227